Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking

Journal of Nutritional Biochemistry

Volumn 26, Issue 1, 2015, Pages 44-56

  Saeed, Mohamed ^a   Kadioglu, Onat ^a   Khalid, Hassan ^b   Sugimoto, Yoshikazu ^c   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Flavonoids; Multidrug resistance; Natural products, Pharmacogenomics, Molecular docking and modelling

Indexed keywords

ABC TRANSPORTER B5; APIGENIN; BREAST CANCER RESISTANCE PROTEIN; DOCETAXEL; DOXORUBICIN; FLAVONOID; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL; ABC TRANSPORTER; MESSENGER RNA; POLYPHENOL; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; AUTOPHAGY; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DETOXIFICATION; DIET; DRUG DETERMINATION; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOLECULAR DOCKING; MOUSE; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PHARMACOGENOMICS; PROTEIN CLEAVAGE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL LINE; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGY; CLUSTER ANALYSIS; DRUG RESISTANCE; GENETICS; IC50; METABOLISM; MULTIDRUG RESISTANCE; PHARMACOGENETICS; PROTEIN CONFORMATION;

MURINAE;

ANIMALS; APIGENIN; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYPHENOLS; PROTEIN CONFORMATION; RNA, MESSENGER;

EID: 84926254640     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.09.008     Document Type: Article

References (94)

1. Miean K.H., Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 2001, 49:3106-3112.
2. Ninfali P., Angelino D. Nutritional and functional potential of Beta vulgaris cicla and rubra. Fitoterapia 2013, 89:188-199.
3. Dordevic S., Cakic M., Amr S. The extraction of apigenin and luteolin from the Sage Salvia Officinalis L. from Jordan. Working Living Environ Prot 2000, 1:87-93.
4. Afzal M., Al-oriquat G., Al-Hassan J., Muhammad N. Flavone glycosides from Lawsonia inermis. Heterocycles 1980, 14:1973-1976.
5. Kumar S., Sharma A. Apigenin: the anxiolytic constituent of Turnera aphrodisiaca. Pharm Biol 2006, 44:84-90.
6. Khalid H., Abdalla W., Abdelgadir H., Opatz T., Efferth T. Gems from traditional north-African medicine: medicinal and aromatic plants from Sudan. Nat Prod Bioprospect 2012, 2:92-103.
7. Schreiber A., Carle R., Reinhard E. On the accumulation of apigenin in chamomile flowers. Planta Med 1990, 56:179-181.
8. Patel D., Shukla S., Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol 2007, 30:233-245.
9. Middleton E., Kandaswami C., Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000, 52:673-751.
10. Zheng P.W., Chiang L.C., Lin C.C. Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci 2005, 76:1367-1379.
11. Plaumann B., Fritsche M., Rimpler H., Brandner G., Hess R.D. Flavonoids activate wild-type p53. Oncogene 1996, 13:1605-1614.
12. Wang W., Heideman L., Chung C.S., Pelling J.C., Koehler K.J., Birt D.F. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 2000, 28:102-110.
13. Long X., Fan M., Bigsby R.M., Nephew K.P. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. Mol Cancer Ther 2008, 7:2096-2108.
14. Efferth T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 2001, 1:45-65.
15. Shukla S., Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther 2006, 5:843-852.
16. Budhraja A., Gao N., Zhang Z., Son Y.O., Cheng S., Wang X., et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther 2012, 11:132-142.
17. Lin C.C., Chuang Y.J., Yu C.C., Yang J.S., Lu C.C., Chiang J.H., et al. Apigenin induces apoptosis through mitochondrial dysfunction in U-2 OS human osteosarcoma cells and inhibits osteosarcoma xenograft tumor growth in vivo. J Agric Food Chem 2012, 60:11395-11402.
18. Mafuvadze B., Liang Y., Besch-Williford C., Zhang X., Hyder S.M. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Hormones Cancer 2012, 3:160-171.
19. Benderra Z., Faussat A.M., Sayada L., Perrot J.Y., Chaoui D., Marie J.P., et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004, 10:7896-7902.
20. Clarke R., Leonessa F., Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 2005, 32:S9-S15.
21. Damiani D., Tiribelli M., Calistri E., Geromin A., Chiarvesio A., Michelutti A., et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006, 91:825-828.
22. Doxani C., Voulgarelis M., Zintzaras E. MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis. Biomarkers 2013, 18:425-435.
23. Kim B., Fatayer H., Hanby A.M., Horgan K., Perry S.L., Valleley E.M., et al. Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS One 2013, 8:e62766.
24. Murphy G.F., Wilson B.J., Girouard S.D., Frank N.Y., Frank M.H. Stem cells and targeted approaches to melanoma cure. Mol Aspects Med 2013, 39:33-49.
25. Kimmig A., Gekeler V., Neumann M., Frese G., Handgretinger R., Kardos G., et al. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 1990, 50:6793-6799.
26. Gillet J.P., Efferth T., Steinbach D., Hamels J., de Longueville F., Bertholet V., et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 2004, 64:8987-8993.
27. Kawanobe T., Kogure S., Nakamura S., Sato M., Katayama K., Mitsuhashi J., et al. Expression of human ABCB5 confers resistance to taxanes and anthracyclines. Biochem Biophys Res Commun 2012, 418:736-741.
28. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998, 95:15665-15670.
29. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch P., Weber H.O., et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003, 64:382-394.
30. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988, 48:589-601.
31. O'Brien J., Wilson I., Orton T., Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000, 267:5421-5426.
32. Kuete V., Wiench B., Hegazy M.E., Mohamed T.A., Fankam A.G., Shahat A.A., et al. Antibacterial activity and cytotoxicity of selected Egyptian medicinal plants. Planta Med 2012, 78:193-199.
33. Rubinstein L.V., Shoemaker R.H., Paull K.D., Simon R.M., Tosini S., Skehan P., et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990, 82:1113-1118.
34. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009, 30:2785-2791.
35. Kelley L.A., Sternberg M.J. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 2009, 4:363-371.
36. Zhao W., Sachsenmeier K., Zhang L., Sult E., Hollingsworth R.E., Yang H. A new bliss independence model to analyze drug combination data. J Biomol Screen 2014, 19:817-821.
37. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989, 81:1088-1092.
38. Efferth T., Konkimalla V.B., Wang Y.F., Sauerbrey A., Meinhardt S., Zintl F., et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 2008, 14:2405-2412.
39. Efferth T., Klett T., Mattern J., Osswald H., Pommerenke E.W., Stohr M., et al. Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo. Anticancer Res 1991, 11:1275-1279.
40. Dixit D., Sharma V., Ghosh S., Mehta V.S., Sen E. Inhibition of casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 2012, 3:e271.
41. Chen K.G., Valencia J.C., Gillet J.P., Hearing V.J., Gottesman M.M. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res 2009, 22:740-749.
42. Grimm M., Krimmel M., Polligkeit J., Alexander D., Munz A., Kluba S., et al. ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma. Eur J Cancer 2012, 48:3186-3197.
43. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
44. Efferth T., Osieka R. Clinical relevance of the MDR - a gene and it's gene product, P-glycoprotein, for cancer chemotherapy. Tumor Diagn Ther 1993, 14:238-243.
45. Lin K.K., Goodell M.A. Detection of hematopoietic stem cells by flow cytometry. Methods Cell Biol 2011, 103:21-30.
46. Summer R., Kotton D.N., Sun X., Ma B., Fitzsimmons K., Fine A. Side population cells and Bcrp1 expression in lung. Am J Physiol Lung Cell Mol Physiol 2003, 285:L97-L104.
47. Cooray H.C., Blackmore C.G., Maskell L., Barrand M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002, 13:2059-2063.
48. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001, 61:3458-3464.
49. Frank N.Y., Margaryan A., Huang Y., Schatton T., Waaga-Gasser A.M., Gasser M., et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65:4320-4333.
50. Hadjeri M., Barbier M., Ronot X., Mariotte A.M., Boumendjel A., Boutonnat J. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues. J Med Chem 2003, 46:2125-2131.
51. Angelini A., Di Ilio C., Castellani M.L., Conti P., Cuccurullo F. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J Biol Regul Homeost Agents 2010, 24:197-205.
52. Zhu Y., Liu C., Nadiminty N., Lou W., Tummala R., Evans C.P., et al. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther 2013, 12:1829-1836.
53. Zeino M., Saeed M.E., Kadioglu O., Efferth T. The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein-a well-known, yet poorly understood drug transporter. Investig New Drugs 2014, 32:618-625.
54. Jin M.S., Oldham M.L., Zhang Q., Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012, 490:566-569.
55. Loo T.W., Clarke D.M. Identification of the distance between the homologous halves of P-glycoprotein that triggers the high/low ATPase activity switch. J Biol Chem 2014, 289:8484-8492.
56. Badhan R., Penny J. In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur J Med Chem 2006, 41:285-295.
57. Zapata-Torres G., Opazo F., Salgado C., Munoz J.P., Krautwurst H., Mascayano C., et al. Effects of natural flavones and flavonols on the kinase activity of Cdk5. J Nat Prod 2004, 67:416-420.
58. Lin J.K., Chen Y.C., Huang Y.T., Lin-Shiau S.Y. Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J Cell Biochem Suppl 1997, 28-29:39-48.
59. Hagiwara M., Inoue S., Tanaka T., Nunoki K., Ito M., Hidaka H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem Pharmacol 1988, 37:2987-2992.
60. Efferth T., Gillet J.P., Sauerbrey A., Zintl F., Bertholet V., de Longueville F., et al. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2006, 5:1986-1994.
61. Efferth T. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem 2012, 19:5735-5744.
62. Quintas-Cardama A., Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 2013, 19:1933-1940.
63. Yang M.H., Zhao M.Y., Wang Z., Kang R., He Y.L., Yin X.C., et al. WAVE1 regulates P-glycoprotein expression via Ezrin in leukemia cells. Leuk Lymphoma 2011, 52:298-309.
64. Kang R., Tang D., Yu Y., Wang Z., Hu T., Wang H., et al. WAVE1 regulates Bcl-2 localization and phosphorylation in leukemia cells. Leukemia 2010, 24:177-186.
65. Kuramoto K., Uesaka T., Kimura A., Kobayashi M., Watanabe H., Katoh O. ZK7, a novel zinc finger gene, is induced by vascular endothelial growth factor and inhibits apoptotic death in hematopoietic cells. Cancer Res 2000, 60:425-430.
66. Le X.F., Bast R.C. Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 2011, 12:260-269.
67. Petitprez A., Larsen A.K. Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. Curr Pharm Des 2013, 19:958-964.
68. De Luca A., D'Alessio A., Gallo M., Maiello M.R., Bode A.M., Normanno N. Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. Cell Cycle 2013, 13.
69. Franzen C.A., Amargo E., Todorovic V., Desai B.V., Huda S., Mirzoeva S., et al. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism. Cancer Prev Res (Phila) 2009, 2:830-841.
70. Ganesan S. MYC, PARP1, and chemoresistance: BIN there, done that?. Sci Signal 2011, 4:pe15.
71. Torigoe T., Izumi H., Ishiguchi H., Yoshida Y., Tanabe M., Yoshida T., et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005, 5:15-27.
72. Yin F., Giuliano A.E., Van Herle A.J. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res 1999, 19:4297-4303.
73. Kim S.H., Kang J.G., Kim C.S., Ihm S.H., Choi M.G., Yoo H.J., et al. Apigenin induces c-Myc-mediated apoptosis in FRO anaplastic thyroid carcinoma cells. Mol Cell Endocrinol 2013, 369:130-139.
74. Garcia-Santisteban I., Peters G.J., Giovannetti E., Rodriguez J.A. USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. Mol Cancer 2013, 12:91.
75. Shen M., Chan T.H., Dou Q.P. Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization. Anti Cancer Agents Med Chem 2012, 12:891-901.
76. Efferth T., Greten H. Autophagy by natural products in cancer cells. Biochem Anal Biochem 2012, 1.
77. Sui X., Chen R., Wang Z., Huang Z., Kong N., Zhang M., et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 2013, 4:e838.
78. Ruela-de-Sousa R.R., Fuhler G.M., Blom N., Ferreira C.V., Aoyama H., Peppelenbosch M.P. Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis 2010, 1:e19.
79. Tong X., Smith K.A., Pelling J.C. Apigenin, a chemopreventive bioflavonoid, induces AMP-activated protein kinase activation in human keratinocytes. Mol Carcinog 2012, 51:268-279.
80. Cao X., Liu B., Cao W., Zhang W., Zhang F., Zhao H., et al. Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells. Chin Journal Cancer Res 2013, 25:212-222.
81. Jang M., Kim S.S., Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 2013, 45:e45.
82. Gallagher E.J., LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 2011, 1243:54-68.
83. Efferth T., Fabry U., Glatte P., Osieka R. Increased induction of apoptosis in mononuclear cells of a glucose-6-phosphate dehydrogenase deficient patient. J Mol Med 1995, 73:47-49.
84. Efferth T., Fabry U., Osieka R. DNA damage and apoptosis in mononuclear cells from glucose-6-phosphate dehydrogenase-deficient patients (G6PD Aachen variant) after UV irradiation. J Leukoc Biol 2001, 69:340-342.
85. Townsend D.M., Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22:7369-7375.
86. Tew K.D., Townsend D.M. Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification. Drug Metab Rev 2011, 43:179-193.
87. Kachadourian R., Day B.J. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic Biol Med 2006, 41:65-76.
88. Yang J., Wang X.Y., Xue J., Gu Z.L., Xie M.L. Protective effect of apigenin on mouse acute liver injury induced by acetaminophen is associated with increment of hepatic glutathione reductase activity. Food function 2013, 4:939-943.
89. Myhrstad M.C., Carlsen H., Nordstrom O., Blomhoff R., Moskaug J.O. Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med 2002, 32:386-393.
90. Chen W.Y., Hsieh Y.A., Tsai C.I., Kang Y.F., Chang F.R., Wu Y.C., et al. Protoapigenone, a natural derivative of apigenin, induces mitogen-activated protein kinase-dependent apoptosis in human breast cancer cells associated with induction of oxidative stress and inhibition of glutathione S-transferase pi. Investig New Drugs 2011, 29:1347-1359.
91. Huang C.S., Lii C.K., Lin A.H., Yeh Y.W., Yao H.T., Li C.C., et al. Protection by chrysin, apigenin, and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes. Arch Toxicol 2013, 87:167-178.
92. Seligmann J., Twelves C. Tubulin: an example of targeted chemotherapy. Future Med Chem 2013, 5:339-352.
93. Touil Y.S., Fellous A., Scherman D., Chabot G.G. Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization. Nutr Cancer 2009, 61:310-321.
94. Efferth T., Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 2011, 12:122-132.